HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

KD025

specific Rho-associated kinase 2 inhibitor

Networked: 19 relevant articles (7 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 4 or More Rings Heterocyclic Compounds
    - KD025: 19

Experts

1.	Zanin-Zhorov, Alexandra: 5 articles (01/2022 - 11/2014)
2.	Blazar, Bruce R: 4 articles (01/2022 - 11/2014)
3.	Chen, Wei: 4 articles (01/2022 - 11/2014)
4.	Schueller, Olivier: 4 articles (10/2021 - 01/2014)
5.	Weiss, Jonathan M: 4 articles (10/2021 - 11/2014)
6.	Chun, Kwang-Hoon: 3 articles (05/2020 - 01/2018)
7.	Nyuydzefe, Melanie S: 3 articles (01/2017 - 11/2014)
8.	Waksal, Samuel D: 3 articles (01/2017 - 11/2014)
9.	Hill, Geoffrey R: 2 articles (01/2022 - 01/2016)
10.	Trzeciak, Alissa: 2 articles (01/2017 - 01/2016)

Related Diseases

1.	Bronchiolitis Obliterans Syndrome 01/01/2016 - "Here, we report that the selective ROCK2 inhibitor KD025 effectively ameliorates cGVHD in multiple models: a full major histocompatibility complex (MHC) mismatch model of multiorgan system cGVHD with bronchiolitis obliterans syndrome and a minor MHC mismatch model of sclerodermatous GVHD. " 10/01/2021 - "ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease." 03/17/2020 - "KD025 (SLx-2119), the first specific Rho-associated protein kinase 2 (ROCK2) inhibitor, is a potential new drug candidate currently undergoing several phase 2 clinical trials for psoriasis, idiopathic pulmonary fibrosis, chronic graft-versus-host disease, and systemic sclerosis. "
2.	Leukemia 12/01/2020 - "KD025, an anti-adipocyte differentiation drug, enhances the efficacy of conventional chemotherapeutic drugs in ABCG2-overexpressing leukemia cells." 12/01/2020 - "The present study demonstrated that KD025 improved the efficacy of antineoplastic drugs in ABCG2-overexpressing leukemia cells and primary leukemia blast cells derived from patients with leukemia. " 12/01/2020 - "The present findings may provide a novel and useful combinational therapeutic strategy of KD025 and antineoplastic drugs for leukemia patients with ABCG2-mediated MDR." 12/01/2020 - "Taken together, KD025 can sensitize conventional antineoplastic drugs in ABCG2-overexpressing leukemia cells by blocking the pump function of ABCG2 protein. "
3.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/01/2014 - "As one mechanism of protection, KD025 improved cortical perfusion in a distal middle cerebral artery occlusion model, implicating enhanced collateral flow. " 01/01/2014 - "KD025 dose-dependently reduced infarct volume after transient middle cerebral artery occlusion. "
4.	Osteoarthritis 10/14/2023 - "FUNDC1/PFKP-mediated mitophagy induced by KD025 ameliorates cartilage degeneration in osteoarthritis."
5.	Liver Cirrhosis (Hepatic Cirrhosis) 01/01/2022 - "We used the thioacetamide-induced liver fibrosis model to examine the efficacy of administration of the selective ROCK2 inhibitor KD025 to prevent or treat liver fibrosis and its impact on immune composition and function. " 01/01/2022 - "Prophylactic and therapeutic administration of KD025 effectively attenuated thioacetamide-induced liver fibrosis and promoted fibrotic regression. "

Related Drugs and Biologics

1.	Antineoplastic Agents (Antineoplastics)
2.	rho-Associated Kinases
3.	Thioacetamide (Thioacetamid)
4.	belumosudil
5.	nintedanib
6.	Protein Kinases (Protein Kinase)
7.	pirfenidone
8.	Interleukin-17 (Interleukin 17)
9.	Proteins (Proteins, Gene)
10.	interleukin-21 (interleukin 21)

Related Therapies and Procedures

1.	Oral Administration
2.	Intraperitoneal Injections